Stimulatory Adrenocortical Effects of a Selective Estrogen Receptor Modulator in Ovariectomized Female Macaques

2011 ◽  
Vol 40 (1) ◽  
pp. 55-61 ◽  
Author(s):  
Charles E. Wood ◽  
Ronda C. Stavisky ◽  
Jette Nowak ◽  
Jay R. Kaplan

Here, we report the effects of estrogen and the selective estrogen receptor modulator (SERM) levormeloxifene on adrenocortical measures in ovariectomized female cynomolgus monkeys ( Macaca fascicularis). Animals were randomized into one of five treatment groups, each containing 23 to 26 animals: (1) placebo, (2) 0.016 mg/kg 17β-estradiol (E2), (3) 0.5 mg/kg levormeloxifene (L1), (4) 1.0 mg/kg levormeloxifene (L2), and (5) 5.0 mg/kg levormeloxifene (L3). Treatments were administered orally each day for 18 mo. All doses of levormeloxifene resulted in adrenal weights at least 50% greater than placebo ( p < .0001 for all). The target dose of levormeloxifene (L2) resulted in higher serum concentrations of cortisol (+63%), dehydroepiandrosterone-sulfate (+73%), and androstenedione (+37%) compared with the placebo group ( p < .05 for all). In contrast, E2 resulted in no significant differences in adrenal weight or adrenocortical steroids. Oral E2 and all SERM doses resulted in similar reductions in serum gonadotropins and at least threefold greater uterine weight versus placebo ( p < .0001 for all). Results indicate that the SERM levormeloxifene, in contrast to E2, may have robust stimulatory effects on adrenocortical hormones in a postmenopausal model. These findings warrant further investigation into long-term SERM effects on adrenocortical function.

2012 ◽  
Vol 124 (1) ◽  
pp. 134-141 ◽  
Author(s):  
Iris L. Romero ◽  
WooSeok Lee ◽  
Anirban K. Mitra ◽  
Ilyssa O. Gordon ◽  
Yan Zhao ◽  
...  

2008 ◽  
Vol 7 (10) ◽  
pp. 4373-4383 ◽  
Author(s):  
Xuemei Zhao ◽  
Ekaterina G. Deyanova ◽  
Laura S. Lubbers ◽  
Pete Zafian ◽  
Jenny J. Li ◽  
...  

2013 ◽  
Vol 41 (7) ◽  
pp. 1001-1010 ◽  
Author(s):  
Rick Perry ◽  
Carol A. Thompson ◽  
J. Nicole Earnhardt ◽  
David J. Wright ◽  
Steven Bailey ◽  
...  

2009 ◽  
pp. n/a-n/a
Author(s):  
Chris Petucci ◽  
Tom Lloyd ◽  
Heather A. Harris ◽  
Xiaochun Zhang ◽  
Vargheese M. Chennathukuzhi ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Hyemin Jeong ◽  
In Young Kim ◽  
Eun-Kyung Bae ◽  
Chan Hong Jeon ◽  
Kwang-Sung Ahn ◽  
...  

AbstractAnkylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM) lasofoxifene (Laso) on disease activity of SpA. Mice were randomized into zymosan-treated, zymosan + 17β-estradiol (E2)-treated, and zymosan + Laso-treated groups. Arthritis was assessed by 18F-fluorodeoxyglucose (18F-FDG) small-animal positron emission tomography/computed tomography and bone mineral density (BMD) was measured. Fecal samples were collected and 16S ribosomal RNA gene sequencing was used to determine gut microbiota differences. Both zymosan + E2-treated mice and zymosan + Laso-treated mice showed lower arthritis clinical scores and lower 18F-FDG uptake than zymosan-treated mice. BMD was significantly higher in zymosan + E2-treated mice and zymosan + Laso-treated mice than zymosan-treated mice, respectively. Fecal calprotectin levels were significantly elevated at 8 weeks after zymosan injection in zymosan-treated mice, but it was not significantly changed in zymosan + E2-treated mice and zymosan + Laso-treated mice. Gut microbiota diversity of zymosan-treated mice was significantly different from zymosan + E2-treated mice and zymosan + Laso-treated mice, respectively. There was no significant difference in gut microbiota diversity between zymosan + E2-treated mice and zymosan + Laso -treated mice. Laso inhibited joint inflammation and enhanced BMD in SKG mice, a model of SpA. Laso also affected the composition and biodiversity of gut microbiota. This study provides new knowledge regarding that selected SpA patients could benefit from SERM treatment.


2009 ◽  
Vol 16 (6) ◽  
pp. 1109-1115 ◽  
Author(s):  
David F. Archer ◽  
JoAnn V. Pinkerton ◽  
Wulf H. Utian ◽  
José C. Menegoci ◽  
Tobie J. de Villiers ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document